[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 11 of about 11
1. Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA: Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer; 2007 Sep 15;110(6):1264-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
  • BACKGROUND: The authors recently reported on the role of cyclin E in differentiating ovarian/primary peritoneal carcinoma from malignant peritoneal mesothelioma using gene expression arrays.
  • In the current study, they analyzed the expression of low-molecular weight (LMW) forms of cyclin E in ovarian carcinoma, malignant mesothelioma, and benign reactive effusions.
  • METHODS: Cyclin E protein expression was analyzed in 98 effusions (72 ovarian carcinomas, 14 malignant mesotheliomas, and 12 reactive specimens) using immunoblotting.
  • The correlations between cyclin E expression in ovarian carcinoma and clinical parameters, including chemotherapy response, were analyzed.
  • RESULTS: LMW forms of cyclin E were identified in 54 of 72 ovarian carcinoma effusions (75%) compared with 1 of 14 malignant mesothelioma effusions (7%) and 1 of 12 reactive effusions (8%) (P < .001).
  • Their presence in ovarian carcinoma was associated with a higher percentage of cyclin E-positive cells (P = .001) and increased staining intensity (P < .001) using immunohistochemistry.
  • The presence of a higher percentage of cyclin E-positive cells using immunohistochemistry was correlated with shorter progression-free survival (P = .026).
  • No association with chemotherapy response was observed.
  • CONCLUSIONS: LMW forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and were associated with increased protein expression using immunohistochemistry.
  • The expression of LMW cyclin E forms was not associated with chemotherapy response, although it may be a marker of aggressive disease in patients with metastatic ovarian carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / chemistry. Carcinoma / mortality. Cyclin E / analysis. Mesothelioma / chemistry. Mesothelioma / mortality. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Immunoblotting. Immunohistochemistry. Middle Aged. Molecular Weight. Survival Analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17647260.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin E
  •  go-up   go-down


2. Moore AJ, Parker RJ, Wiggins J: Malignant mesothelioma. Orphanet J Rare Dis; 2008;3:34
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma.
  • Malignant mesothelioma is a fatal asbestos-associated malignancy originating from the lining cells (mesothelium) of the pleural and peritoneal cavities, as well as the pericardium and the tunica vaginalis.
  • The exact prevalence is unknown but it is estimated that mesotheliomas represent less than 1% of all cancers.
  • Pleural malignant mesothelioma is the most common form of mesothelioma.
  • Mesothelioma is directly attributable to occupational asbestos exposure with a history of exposure in over 90% of cases.
  • There is also evidence that mesothelioma may result from both para-occupational exposure and non-occupational "environmental" exposure.
  • Idiopathic or spontaneous mesothelioma can also occur in the absence of any exposure to asbestos, with a spontaneous rate in humans of around one per million.
  • Distinguishing malignant from benign pleural disease can be challenging.
  • The most helpful CT findings suggesting malignant pleural disease are 1) a circumferential pleural rind, 2) nodular pleural thickening, 3) pleural thickening of > 1 cm and 4) mediastinal pleural involvement.
  • Involvement of a multidisciplinary team is recommended to ensure prompt and appropriate management, using a framework of radiotherapy, chemotherapy, surgery and symptom palliation with end of life care.
  • Life expectancy in malignant mesothelioma is poor, with a median survival of about one year following diagnosis.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / pathology. Pleural Neoplasms / diagnosis. Pleural Neoplasms / pathology
  • [MeSH-minor] Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4225-31 [16857795.001]
  • [Cites] Semin Diagn Pathol. 2006 Feb;23(1):56-60 [17044196.001]
  • [Cites] Orphanet J Rare Dis. 2006;1:44 [17090323.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(1):CD005574 [17253564.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Apr;19(3):182-7 [17359904.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):666-72 [17289801.001]
  • [Cites] J Thorac Oncol. 2006 May;1(4):289-95 [17409872.001]
  • [Cites] Exp Anim. 2007 Apr;56(2):155-9 [17460361.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2928-35 [17504993.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):339-443 [17534183.001]
  • [Cites] Radiother Oncol. 2007 Jul;84(1):18-22 [17588698.001]
  • [Cites] Oncologist. 2007 Jul;12(7):850-63 [17673616.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1196-202 [17429100.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1366-74 [17674974.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):350-7 [17467922.001]
  • [Cites] Thorax. 2007 Nov;62 Suppl 2:ii1-ii19 [17965072.001]
  • [Cites] Eur Respir J. 2007 Nov;30(5):1021 [17978160.001]
  • [Cites] Occup Med (Lond). 2007 Dec;57(8):564-8 [17675661.001]
  • [Cites] Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272 [18154821.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):370-3 [18156144.001]
  • [Cites] Mayo Clin Proc. 2008 Feb;83(2):235-50 [18241636.001]
  • [Cites] Ann Thorac Surg. 2008 Mar;85(3):1049-55 [18291195.001]
  • [Cites] Arch Pathol Lab Med. 2008 Mar;132(3):397-401 [18318582.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3 [18329481.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):411-20 [18061303.001]
  • [Cites] Curr Opin Pulm Med. 2008 Jul;14(4):303-9 [18520263.001]
  • [Cites] Regul Toxicol Pharmacol. 2008 Oct;52(1 Suppl):S223-31 [18022298.001]
  • [Cites] Occup Med (Lond). 2005 Mar;55(2):79-87 [15757980.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Aug;18(2):143-6 [10925221.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3912-7 [11099320.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Toxicol Lett. 2002 Feb 28;127(1-3):251-7 [12052665.001]
  • [Cites] Lung Cancer. 2002 Nov;38(2):111-21 [12399121.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):606-16 [12573747.001]
  • [Cites] Thorax. 2003 May;58 Suppl 2:ii29-38 [12728148.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Ann Diagn Pathol. 2003 Oct;7(5):321-32 [14571437.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):105-19 [14730040.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):257-60 [14760119.001]
  • [Cites] Thorax. 2004 Feb;59(2):144-8 [14760156.001]
  • [Cites] Chest. 2004 Feb;125(2):489-93 [14769729.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(1):CD002916 [14973997.001]
  • [Cites] Int J Occup Environ Health. 2004 Jan-Mar;10(1):26-39 [15070023.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jul;128(1):138-46 [15224033.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Aug 15;170(4):377-82 [15142871.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1406-12 [15319247.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1157-66 [15451223.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1183-5 [15451229.001]
  • [Cites] Q J Med. 1976 Jul;45(179):427-49 [948545.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):19-25 [6174494.001]
  • [Cites] Acta Clin Belg. 1989;44(3):199-201 [2816228.001]
  • [Cites] AJR Am J Roentgenol. 1990 Mar;154(3):487-92 [2106209.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):4-9 [1689538.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):433-8 [1995528.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Nov;3(6):315-7 [1720658.001]
  • [Cites] Australas Radiol. 1994 Aug;38(3):212-4 [7524472.001]
  • [Cites] Lancet. 1995 Mar 4;345(8949):535-9 [7776771.001]
  • [Cites] J Comput Assist Tomogr. 1995 May-Jun;19(3):370-4 [7790544.001]
  • [Cites] Chest. 1995 Sep;108(3):754-8 [7656629.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1995;7(5):317-8 [8580058.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • [Cites] Eur Respir J. 1996 Jun;9(6):1206-10 [8804939.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):288-94; discussion 294-6 [8813257.001]
  • [Cites] Thorax. 1997 Jun;52(6):507-12 [9227715.001]
  • [Cites] Eur J Cancer Prev. 1997 Apr;6(2):162-6 [9237066.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1997 Oct;9(4):367-72 [9352954.001]
  • [Cites] Thorax. 1997 Aug;52 Suppl 3:S52-7 [9381428.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):269-73 [9602260.001]
  • [Cites] Respir Med. 1998 Apr;92(4):691-2 [9659538.001]
  • [Cites] Chest. 1998 Sep;114(3):713-22 [9743156.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4505-9 [9788590.001]
  • [Cites] Radiology. 1999 Jan;210(1):277-81 [9885620.001]
  • [Cites] Occup Environ Med. 1999 Jan;56(1):51-8 [10341747.001]
  • [Cites] Br J Ind Med. 1960 Oct;17:260-71 [13782506.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):587-93 [15668716.001]
  • [Cites] Eur J Surg Oncol. 2005 Apr;31(3):314-20 [15780570.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2602-9 [15805256.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S109-11 [15950789.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S37-40 [15950799.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jan;29(1):14-9 [16343925.001]
  • [Cites] Clin Imaging. 2006 May-Jun;30(3):177-80 [16632152.001]
  • [Cites] Am J Respir Crit Care Med. 2006 May 15;173(10):1155-60 [16456138.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5 [16751058.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD003880 [16856023.001]
  • (PMID = 19099560.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 93
  • [Other-IDs] NLM/ PMC2652430
  •  go-up   go-down


3. Tomobe M, Miyanaga N, Kawai K, Kikuchi K, Uchida K, Takeshima H, Hasegawa Y, Nagasawa T, Akaza H: [Intrascrotal tumors: a clinicopathologic study of 15 cases]. Nihon Hinyokika Gakkai Zasshi; 2000 Sep;91(9):618-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intrascrotal tumors: a clinicopathologic study of 15 cases].
  • PURPOSE: We reviewed cases of intrascrotal tumors treated at our institution except for germ cell testicular tumors.
  • PATIENTS AND METHODS: From 1977 to 1998 (22 years), 120 cases of intrascrotal tumors treated at the University of Tsukuba.
  • Of these, 15 cases (12.5%) were not germ cell testicular tumors.
  • The patients' ages varied between 2 and 77 years with a mean of 49.6.
  • Tumor weight ranged from 2 to 200 g, with an average of 104.6 g.
  • The histological diagnoses of 15 patients were 8 malignant lymphomas, 2 paratesticular rhabdomyosarcomas, 2 metastatic tumors (origin; stomach and prostate), 1 epidermoid cyst, 1 cyst of tunica testis, and 1 adenomatoid tumor.
  • Five 8 patients died in spite of systemic chemotherapy after an orchiectomy, whereas 2 cases with metastatic tumors died of primary cancer, and two cases with paratesticular rhabdomyosarcoma are still alive and have had no evidence of disease.
  • CONCLUSIONS: Intrascrotal tumors except for germ cell testicular tumors are not common, and consist of various diseases.
  • Therefore, accurate diagnosis and precise treatment is important in the patient with intrascrotal tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11068425.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


Advertisement
4. Vander Salm TJ: Unusual primary tumors of the heart. Semin Thorac Cardiovasc Surg; 2000 Apr;12(2):89-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual primary tumors of the heart.
  • Primary tumors of the heart, with the exception of atrial myxomas, occur rarely; tumors metastatic to or directly invasive of the heart are far more common.
  • About 75% of primary tumors are benign, and 75% of these are atrial myxomas.
  • The benign tumors include rhabdomyomas, fibromas, papillary fibroelastomas, hemangiomas, pericardial cysts, lipomas, hamartomas, teratomas, mesotheliomas, and paragangliomas or pheochromocytomas.
  • The malignant tumors consist of various sarcomas: myxosarcoma, liposarcoma, angiosarcoma, fibrosarcoma, leiomyosarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma, reticulum cell sarcoma, neurofibrosarcoma, and malignant fibrous histiocytoma.
  • Cardiac tumors produce a large variety of symptoms through any of 4 mechanisms.
  • Bits of tumor can embolize, causing systemic deficits when the tumors are on the left side of the heart.
  • Finally, the tumors may cause systemic or constitutional symptoms.
  • Some tumors, of course, produce no symptoms and become evident as incidental findings.
  • The most useful diagnostic tool is the echocardiogram, which in almost all cases precisely locates the tumor and defines its extent.
  • The echocardiographic appearance may also allow quite accurate prediction of the tumor type and whether it is malignant or benign.
  • Magnetic resonance imaging serves as the next most important test where the density of T1 and T2 images may allow tumor cell type identification.
  • With few exceptions, these tumors require operative excision.
  • Most benign tumors can be resected completely; a few, because of their large size, cannot be, and only tumor debulking may be possible.
  • Many of the malignant tumors cannot be resected completely, either because of the extent of local spread and invasion or because of the frequent distant metastases.
  • Transplantation may also be an option for those with extensive local disease.
  • The long-term results for resected benign tumors are excellent; the long-term results for sarcomas are very poor, and there are few survivors.
  • For patients with unresectable sarcomas, radiation and chemotherapy may be used, but without great expectation of successful results.
  • [MeSH-minor] Fibroma / diagnosis. Fibroma / surgery. Hamartoma / diagnosis. Hamartoma / surgery. Heart Septum / pathology. Heart Transplantation. Hemangioma / diagnosis. Hemangioma / surgery. Humans. Hypertrophy. Mesothelioma / diagnosis. Mesothelioma / surgery. Pheochromocytoma / diagnosis. Pheochromocytoma / surgery. Prognosis. Rhabdomyoma / diagnosis. Rhabdomyoma / surgery. Teratoma / diagnosis. Teratoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10807431.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 69
  •  go-up   go-down


5. Schwab R, Schneider C, Junge K, Stumpf M, Becker HP, Schumpelick V: [Large solitary fibrous tumors of the pleura as incidental finding. 2 case reports of a rare tumor entity]. Chirurg; 2004 Feb;75(2):200-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Large solitary fibrous tumors of the pleura as incidental finding. 2 case reports of a rare tumor entity].
  • The solitary fibrous tumor (SFT) is a very rare and usually benign neoplasm.
  • This tumor is mostly located in the thoracic cavity, but it has also been reported in numerous sites including liver, skin, and meninges.
  • Solitary fibrous tumors consistently express CD 34 and react negatively to epithelial markers.
  • This absence of expression of epithelial markers, especially cytokeratin, is also useful to distinguish these rare entities from sarcomatous mesotheliomas.
  • The treatment of choice for solitary fibrous tumors is extensive surgical resection.
  • Up to now there is no evidence that radiation and chemotherapy are effective.
  • In cases of benign classification (60-80%), the recurrence rate was only 2% after surgical excision.
  • One-half of the patients with malignant tumors can be cured; the rest develop recurrences and metastases more often.
  • We report two cases of a 65- and a 75-year-old male patient with huge intrathoracic solitary fibrous subpleural tumors, discovered incidentally on routine chest X-ray.
  • [MeSH-major] Incidental Findings. Neoplasms, Fibrous Tissue / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Pleura / pathology. Pleura / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiovasc Surg (Torino). 2002 Aug;43(4):559-61 [12124574.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Oct;259(9):470-3 [12386749.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Am J Dermatopathol. 1999 Jun;21(3):213-9 [10380040.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12 ):1501-11 [9850176.001]
  • [Cites] J Thorac Cardiovasc Surg. 1978 Mar;75(3):363-72 [633933.001]
  • [Cites] J Pathol. 1997 Apr;181(4):362-7 [9196431.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Feb;19(2):185-9 [11167110.001]
  • [Cites] Chirurg. 1999 Aug;70(8):949-52 [10460294.001]
  • [Cites] Pathol Int. 1998 Jan;48(1):47-52 [9589464.001]
  • [Cites] Thorax. 1991 Dec;46(12):930-1 [1792643.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):217-24 [8712177.001]
  • [Cites] Langenbecks Arch Surg. 2000 Dec;385(8):521-5 [11201008.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):63-8 [10665915.001]
  • [Cites] Cancer. 1979 Oct;44(4):1465-75 [498021.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1841-7 [10362810.001]
  • (PMID = 14991184.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Meignan M, Paone G: [18-Fluoro-deoxy-glucose (15FDG) positon emission tomography (PET) for the evaluation of malignant pleural disease]. Rev Pneumol Clin; 2006 Apr;62(2):128-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18-Fluoro-deoxy-glucose (15FDG) positon emission tomography (PET) for the evaluation of malignant pleural disease].
  • [Transliterated title] La tomographie par émission de positons (TEP) au 18-fluoro-déoxy-glucose (18FDG) dans l'évaluation de la pathologie pleurale maligne.
  • Use of 18FDG-PET for malignant tumors of the pleura raises certain technical difficulties because of the small size of the tumors and their diffuse distribution, but hybrid PET/CT machines offer a better localization of FDG uptake.
  • FDG-PET can discriminate between malignant and benign pleural tumors FDG uptake in the pleura is the best diagnostic criteria of malignancy.
  • The presence of FDG uptake in pleural effusion is less discriminate between benign and malignant disease.
  • For mesotheliomas, FDG-PET can difference malignant tumors from benign tumors of the pleura on the basis of the SUV value (<or > 2).
  • It does not enable detection of mediastinal node involvement and regional extension but is effective in detecting extra-thoracic regional spread not identified with other imaging methods.
  • FDG-PET can thus affect the therapeutic strategy.
  • SUV<4 associated with an epithelial tumor is a sign of good prognosis at three years.
  • SUV > 4 associated with a non-epithelial tumor is a sign of poor prognosis.
  • For mesotheliomas, FDG uptake can be used to assess the effect of chemotherapy and determine whether patients are good responders or not.
  • [MeSH-major] Fluorodeoxyglucose F18. Pleural Neoplasms / diagnosis. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Humans. Mesothelioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670667.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 19
  •  go-up   go-down


7. Spanu A, Ginesu F, Pirina P, Solinas ME, Schillaci O, Farris A, Chessa F, Madeddu G, Marongiu P, Falchi A, Nuvoli S, Madeddu G: The usefulness of 99mTc-tetrofosmin SPECT in the detection of intrathoracic malignant lesions. Int J Oncol; 2003 Mar;22(3):639-49
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of 99mTc-tetrofosmin SPECT in the detection of intrathoracic malignant lesions.
  • To evaluate the usefulness of 99mTc-tetrofosmin (TF) SPECT in the detection of intrathoracic malignant lesions, we studied 304 patients, 261 with malignant and 43 with benign lesions; 196 of the former had non-treated primary tumors, 193 lung cancer (LC) and 3 mesotheliomas, 11 had LC recurrences and 54 had metastases from different kinds of tumors.
  • Twenty-nine patients with primary tumors were re-checked after chemotherapy or surgery.
  • Moreover, SPECT was concordant with CT in correctly evaluating the response to chemotherapy or surgery in all monitorized primary tumors cases, except in one in whom only SPECT detected residual tumor.
  • The semiquantitative analysis added useful information in differentiating malignant from benign lesions and in monitoring the response to chemo-therapy.
  • TF SPECT appears a highly accurate diagnostic method in the detection of intrathoracic malignant lesions, in lungs and pleura, as well as in NSCLC mediastinal lymph node staging and in monitoring treatment effectiveness, playing a complementary role to CT in selected cases.
  • [MeSH-major] Organophosphorus Compounds. Organotechnetium Compounds. Radiopharmaceuticals. Thoracic Neoplasms / radionuclide imaging. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Carcinoma, Non-Small-Cell Lung / surgery. Combined Modality Therapy. False Negative Reactions. False Positive Reactions. Female. Humans. Lung Diseases / radiography. Lung Diseases / radionuclide imaging. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / surgery. Lymphatic Metastasis. Male. Mesothelioma / drug therapy. Mesothelioma / pathology. Mesothelioma / radiography. Mesothelioma / radionuclide imaging. Mesothelioma / surgery. Middle Aged. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm, Residual. Pleural Neoplasms / drug therapy. Pleural Neoplasms / pathology. Pleural Neoplasms / radiography. Pleural Neoplasms / radionuclide imaging. Pleural Neoplasms / surgery. Predictive Value of Tests. Sensitivity and Specificity. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12579319.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


8. García-González J, Villanueva C, Fernández-Aceñero MJ, Paniagua P: Paratesticular desmoplastic small round cell tumor: case report. Urol Oncol; 2005 Mar-Apr;23(2):132-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular desmoplastic small round cell tumor: case report.
  • BACKGROUND: The desmoplastic small round cell tumor has recently been separated from other small round cell tumors because of its characteristic pathological and clinical features.
  • They are usually intra-abdominal tumors affecting young people and have classically been associated with a bad prognosis.
  • However, in recent years there have reports on desmoplastic small round cell tumors affecting other body regions, including the paratesticular area.
  • CASE PRESENTATION: We report the case of a 23-year-old male, that consulted on a progressive enlargement of the right hemiscrotum in the last year and a half.
  • Physical examination revealed a round elastic firm 2 to 3 cm mass distal to the tail of the epididymis, which was excised with a preoperative diagnosis of adenomatoid tumor.
  • However, histological and immunohistochemical diagnosis confirmed a desmoplastic small round cell tumor.
  • The extension study included a computed tomography scan and a plain chest radiograph, that showed no metastasis.
  • The patient received chemoradiation therapy with methotrexate, dacarbacin, cyclophosphamide, actinomycin D and vincristin, but had to be changed to a vincristin, actinomycin D, cyclophosphamide and adriamicin scheme on severe toxicity.
  • He completed five cycles of the chemotherapy with moderate toxicity.
  • Today, 6 years after diagnosis the patient remains well and free of disease.
  • CONCLUSIONS: Recent reviews on desmoplastic small round cell tumor affecting the paratesticular area have shown a better prognosis for tumors of this origin compared to abdominal ones.
  • We should include this lesion among the differential diagnosis of paratesticular tumors, mainly in children and adolescents.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Humans. Male

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869999.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Rizkalla HF, Higgins M, Kelehan P, O'Herlihy C: Pathological findings associated with the presence of a mirena intrauterine system at hysterectomy. Int J Gynecol Pathol; 2008 Jan;27(1):74-8
Hazardous Substances Data Bank. LEVONORGESTREL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological findings associated with the presence of a mirena intrauterine system at hysterectomy.
  • However, in some women, IUS treatment fails to reduce menstrual flow, and surgical treatment, including hysterectomy, is necessary.
  • We have reviewed the histopathological findings on the uteri of 44 women undergoing hysterectomy because of menorrhagia after unsuccessful IUS treatment to assess whether a potentially unresponsive cohort could be identified.
  • A retrospective review of 44 hysterectomy specimens was performed between October 1999 and April 2006 on women who underwent unsuccessful treatment of menorrhagia with the IUS.
  • Thirty hysterectomy specimens contained benign leiomyomata with associated reduced reactivity in the uterine cavity and incomplete suppression of the endometrium.
  • In addition to leiomyomas, 1 specimen had an atypical polypoid adenomyoma and 1 had a benign adenomatoid tumor.
  • Most women (86%) undergoing hysterectomy because of abnormal uterine bleeding with a Mirena IUS in situ had uterine abnormalities, as revealed by pathological review.
  • Although recent reports have indicated that the IUS can be used successfully in the treatment of menorrhagia due to uterine fibroids, most cases of hysterectomies in this series after failed IUS suppression of menorrhagia contained uterine fibroids.
  • [MeSH-major] Intrauterine Devices, Medicated. Levonorgestrel / therapeutic use. Menorrhagia / drug therapy. Uterus / drug effects. Uterus / pathology
  • [MeSH-minor] Endometrial Hyperplasia / complications. Endometrial Hyperplasia / pathology. Endometriosis / complications. Endometriosis / pathology. Female. Humans. Hysterectomy. Leiomyoma / complications. Leiomyoma / pathology. Retrospective Studies. Treatment Failure. Uterine Neoplasms / complications. Uterine Neoplasms / pathology


10. Piccin A, Conneally E, Lynch M, McMenamin ME, Langabeer S, McCann S: Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia. Leuk Lymphoma; 2006 Jul;47(7):1394-6
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia.
  • [MeSH-major] Adenomatoid Tumor / diagnosis. Adenomatoid Tumor / drug therapy. Antineoplastic Agents / pharmacology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / pharmacology. Pyrimidines / pharmacology. Testicular Neoplasms / diagnosis. Testicular Neoplasms / drug therapy


11. Rodriguez-Panadero F: Malignant pleural diseases. Monaldi Arch Chest Dis; 2000 Feb;55(1):17-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of malignant pleural effusions has been increasing over the last few decades (mainly due to the absolute increase in several types of cancers, especially those of lung and breast origin) and they account for up to 50% of the exudates in many clinical series.
  • Although pleural malignancies are thought to present most frequently with a pleural effusion, several autopsy series, including the current one, found a pleural effusion present in little more than half of the cases of malignant pleural involvement (55% in this series).
  • Thus, many pleural malignancies without effusion might pass unnoticed in clinical practice, especially in metastatic disease.
  • Primary malignancies of the pleura (mesotheliomas) are associated with asbestos exposure in about two-thirds of cases, and they frequently present with chest pain, sometimes associated with a pleural effusion.
  • Benign pleural plaques can coexist with malignant mesothelioma, and this association should be suspected when long-standing plaques change in shape or size over the years, and especially if chest pain develops in a previously asymptomatic patient.
  • Metastatic pleural involvement is much more frequent than mesotheliomas, and its most frequent mechanism is the vascular spreading of tumour cells from distant organs to the lungs, and on to the visceral and parietal pleura.
  • Thoracoscopy has the additional advantage of allowing pleurodesis with talc poudrage if clear tumour lesions are found in the pleura.
  • In cases of malignant effusion which are not sensitive to chemotherapy, pleurodesis is the treatment of choice for palliation of symptoms, and talc is the most effective agent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10786419.001).
  • [ISSN] 1122-0643
  • [Journal-full-title] Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
  • [ISO-abbreviation] Monaldi Arch Chest Dis
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down






Advertisement